Diabeloop Presents New Real-Life Results of DBLG1® System

Confirmed Improvement in Time in Range +18.4 Percentage Points; Reduction of Time Spent in Hypoglycemia to Only 0.9% PARIS, April 28, 2022 (Newswire.com) – At ATTD 2022 – Diabeloop, a pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany. The data show a constant improvement in Time In Range (70-180 mg/dL) combined…